Popular Articles
Stretch Mark Remedies

LSUHSC Research On How Like Cell Receptor Systems Determine Very Different Functions, Supported By Grant
Andy Catling, PhD, Associate Professor in the Department of Pharmacology and the Stanley S. Scott Cancer Center at LSU Health Sciences Center New Orleans, has been awarded a $177, 500 supplement to his RO1 grant by the National Institute of General Medical Sciences to support his research on the mechanism by which seemingly similar cell receptor systems determine quite different functions influenced by hormones and drugs.
generic viagra online
GP Surgeries Use SMS To Advise Patients On Swine Flu, UK
GP Surgeries in Camden are successfully sending out text messages advising patients on what to do if they think they have Swine Flu.
News of the day
Lilly Advances Second Alzheimer's Disease Treatment Candidate Into Late-Stage Testing By Launching Two Global Trials
Eli Lilly and Company (NYSE: LLY) announced it will begin enrolling patients this month in two separate but identical Phase III clinical trials of solanezumab(i), previously referred to as LY2062430, an anti-amyloid beta monoclonal antibody being investigated as a potential treatment to delay the progression of mild to moderate Alzheimer"s disease. The trials, called EXPEDITION and EXPEDITION 2, will each include a treatment period that lasts 18 months and are expected to enroll a total of 2,000 patients age 55 and over from 16 countries.
Endocrinology

Boston Scientific Announces European Approval For Its Latitude(R) Patient Management System

Boston Scientific Corporation (NYSE: BSX) announced CE Mark for its LATITUDE® Patient Management system. The LATITUDE system remotely monitors patients with implantable cardiac devices, gathering information on both the device and a patient"s heart health status. The system can also detect clinical events between scheduled physician visits and send relevant data directly to a patient"s physician. It will be launched in Europe in a phased approach beginning this week. "The wireless LATITUDE system will enable me to more closely monitor my patients while helping manage hospital workflow," said Konstantin M. Heinroth, M.D., Department of Medicine, Martin Luther-University Halle-Wittenberg, Halle, Germany. "I hope to provide my patients added convenience and the peace of mind that comes from knowing both their device and heart health status can be monitored." "Boston Scientific has enrolled more than 130,000 patients on the LATITUDE system since its introduction in the U.S. in 2006, making it the most rapidly adopted remote cardiac device monitoring system in the industry[1]," said Fred Colen, President, Boston Scientific Cardiac Rhythm Management. "We expect continued success as we introduce the demonstrated benefits of our LATITUDE system to patients and physicians in Europe. Remote monitoring technology provides a significant opportunity to further improve patient care." The LATITUDE system provides physicians actionable information that enables them to see changes in their patient"s cardiac health sooner than regularly scheduled follow-up visits. LATITUDE is the only remote cardiac device monitoring system with an optional wireless weight scale and blood pressure monitor, both of which are recommended by the European Society of Cardiology for the management of Class I heart failure patients. The international version of the LATITUDE system is compatible with the Company"s wireless TELIGEN® implantable cardioverter defibrillator (ICD) and COGNIS® cardiac resynchronization therapy defibrillator (CRT-D), the world"s smallest and thinnest high-energy devices. The first enrollments of European patients onto the LATITUDE system were performed by Dr. J.H. Ruiter at Medisch Centrum Hospital, Alkmaar, Netherlands and Dr. Peter Mortensen, Skejby University Hospital, Aarhus, Denmark. [1] Data based on number of patients at three years post-launch. Data on file. Boston Scientific


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):